Stella Pharma Corporation (TYO:4888)
Japan · Delayed Price · Currency is JPY 311.00
-4.00 (-1.27%)
Aug 6, 2026, 1:03 PM JST
Stella Pharma Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 11,351 | 25,832 | 13,035 | 9,087 | 11,485 | 17,281 | |
Market Cap Growth | -20.59% | 98.17% | 43.45% | -20.88% | -33.54% | - |
Enterprise Value | 9,274 | 23,927 | 10,396 | 7,501 | 10,146 | 14,767 |
Last Close Price | 315.00 | 759.00 | 383.00 | 291.00 | 387.00 | 603.00 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PS Ratio | 35.14 | 79.97 | 13.56 | 33.78 | 50.15 | 172.82 |
PB Ratio | 4.68 | 10.65 | 4.07 | 3.82 | 4.17 | 5.61 |
P/TBV Ratio | 4.76 | 10.84 | 4.13 | 3.91 | 4.27 | 5.74 |
P/FCF Ratio | - | - | 95.85 | - | - | - |
P/OCF Ratio | - | - | 93.11 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 28.71 | 74.08 | 10.82 | 27.88 | 44.31 | 147.68 |
EV/FCF Ratio | - | - | 76.44 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.31 | 0.31 | 0.24 | 0.39 | 0.40 | 0.41 |
Debt / FCF Ratio | - | - | 5.63 | - | - | - |
Net Debt / Equity Ratio | -0.86 | -0.86 | -0.76 | -0.60 | -0.59 | -0.66 |
Net Debt / EBITDA Ratio | 2.88 | 2.88 | 43.57 | 1.96 | 2.10 | 2.86 |
Net Debt / FCF Ratio | 6.02 | 6.02 | -17.94 | 1.60 | 1.90 | 1.80 |
Asset Turnover | 0.07 | 0.07 | 0.21 | 0.07 | 0.05 | 0.03 |
Inventory Turnover | 0.04 | 0.04 | 0.10 | 0.05 | 0.03 | 0.03 |
Quick Ratio | 11.16 | 11.16 | 10.05 | 5.34 | 6.58 | 10.69 |
Current Ratio | 16.81 | 16.81 | 13.44 | 7.98 | 9.01 | 13.56 |
Return on Equity (ROE) | -27.69% | -27.69% | -5.01% | -29.76% | -26.68% | -46.36% |
Return on Assets (ROA) | -9.45% | -9.45% | -1.22% | -11.66% | -11.14% | -13.69% |
Return on Capital Employed (ROCE) | -17.70% | -17.70% | -1.80% | -22.60% | -20.60% | -16.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -6.87% | -3.02% | -1.07% | -8.40% | -6.77% | -4.44% |
FCF Yield | -3.04% | -1.34% | 1.04% | -9.75% | -7.43% | -6.52% |
Buyback Yield / Dilution | -1.93% | -1.93% | -7.76% | -7.27% | -2.83% | -40.17% |